InnoCan Pharma Corporation

INNO

CA45783P1027

Pharmaceuticals

Delayed Canadian Securities Exchange Other stock markets 10:45:38 2024-04-19 am EDT			5-day change	1st Jan Change
0.26 ^CAD	-5.45%		-10.34%	-16.13%

Apr. 01	InnoCan Pharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 25	Innocan Pharma Corporation Announces the Signing of an Agreement with the Hebrew University	CI

InnoCan Pharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022

November 28, 2022 at 04:23 pm EST

InnoCan Pharma Corporation reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was USD 0.749 million compared to USD 0.054 million a year ago. Net loss was USD 0.168 million compared to USD 3.62 million a year ago. Basic loss per share from continuing operations was USD 0.001 compared to USD 0.016 a year ago.
For the nine months, sales was USD 1.42 million compared to USD 0.18 million a year ago. Net loss was USD 2.56 million compared to USD 9.48 million a year ago. Basic loss per share from continuing operations was USD 0.011 compared to USD 0.044 a year ago.

Latest news about InnoCan Pharma Corporation

InnoCan Pharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Innocan Pharma Corporation Announces the Signing of an Agreement with the Hebrew University	Mar. 25	CI
InnoCan Pharma "Paves Its Way" to LPT-CBD Chemistry, Manufacturing and Controls (CMC), "Key Milestones" for FDA Approval	Mar. 25	MT
InnoCan Pharma Corporation announced that it has received CAD 1.98821 million in funding	Mar. 13	CI
Innocan Pharma Corporation Announces Tissue Distribution Study of LPT-CBD to the Brain	Mar. 05	CI
InnoCan Pharma Corporation announced that it expects to receive CAD 3 million in funding	Mar. 04	CI
InnoCan Pharma Corporation Announces Study Findings That Lpt-Cbd Maintain Its Prolonged Release in Rabbits	Feb. 26	CI
InnoCan Pharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 29	CI
InnoCan Pharma Brief: Says "Surge" in revenue Primarily attributable to "Robust" sales performance of Subsidiary, B.I. Sky Global Ltd.	Nov. 29	MT
InnoCan Pharma Brief: Reporting US$4.083 Million In Revenues for Q3 2023 Vs US$749,000 for Q3 2022, representing an increase of 445%	Nov. 29	MT
Innocan Pharma Corporation Announces Promising LPT-CBD Safety Indications	Nov. 03	CI
InnoCan Pharma Completes Second, Final Tranche of Financing; Down Over 3%	23-10-20	MT
InnoCan Pharma Corporation announced that it has received CAD 1.627682 million in funding	23-10-19	CI
InnoCan Pharma Completes First Tranche Private Placement; Down 4.8%	23-10-12	MT
Innocan Pharma Plans Brokered LIFE Offering of Units for Nearly $3 Million	23-09-21	MT
InnoCan Pharma Corporation announced that it expects to receive CAD 3 million in funding	23-09-20	CI
InnoCan Pharma Corporation Announces Appointment of Dr. Joseph V. Pergolizzi to its Scientific Advisory Board	23-09-15	CI
Innocan Pharma Corporation Announces Promising Results from Hair Care Cream Efficacy Test	23-09-05	CI
Innocan Pharma Corporation Announces Clinical Study Results	23-08-28	CI
InnoCan Pharma Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Innocan Pharma Announces Promising Successful Results in Efficacy Trial of Diabetic Foot Relief Treatment	23-08-15	CI
Innocan Pharma Announced "Promising Successful" Results in Efficacy Trial of Diabetic Foot Relief Treatment; Gained 9% Today	23-08-15	MT
InnoCan Pharma Corporation announced that it has received CAD 1.934239 million in funding	23-08-07	CI
InnoCan Pharma Corporation announced that it expects to receive CAD 1.934239 million in funding	23-08-03	CI
InnoCan Pharma Announces Private Placement of Units at a 9% Prime Above Share Price	23-07-25	MT

Chart InnoCan Pharma Corporation

Duration

Period

More charts

Company Profile

Innocan Pharma Corporation is an Israel-based pharmaceutical company active in the medical cannabis industry. It operates through three distinct operating segments: Research, Development, Marketing, Distribution and sales of InnoCan-branded over the counter (OTC) pharmaceutical products; Research and Development of Non-pharmaceutical products for third parties and Research and Development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales. The Company is developing an OTC topical treatments product line and new platform to facilitate the targeted controlled administration of cannabinoids via injection.

Sector

Pharmaceuticals

Calendar

2024-05-09 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
INNOCAN PHARMA CORPORATION	-16.13%	56.14M
ELI LILLY AND COMPANY	+24.97%	672B
NOVO NORDISK A/S	+24.08%	550B
JOHNSON & JOHNSON	-6.35%	351B
MERCK & CO., INC.	+14.95%	317B
ABBVIE INC.	+7.07%	292B
ASTRAZENECA PLC	+3.26%	211B
NOVARTIS AG	+0.78%	203B
PFIZER, INC.	-10.33%	144B
AMGEN INC.	-7.34%	141B